Johnson & Johnson (JNJ) 100.64 $JNJ
Whistleblower Payments Top $300 Million Under False Claims Act in Fiscal Year 2014
PRWeb - 2 hrs 39 mins ago
A review of press releases issued by the Department of Justice since October 1, 2013 conducted by Young Law Group reveals that whistleblowers have been awarded more than $300 million from settlements in qui tam lawsuits in the current fiscal year. The federal government's fiscal year begins on October 1st, leaving more than four months left to add to the impressive amount so far.
Final Glance: Pharmaceuticals companies
AP - Mon May 19, 6:54PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Mon May 19, 6:54PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Minnesota bans anti-bacterial chemical from soaps
By STEVE KARNOWSKI - AP - Mon May 19, 5:22PM CDT
MINNEAPOLIS (AP) — It's widely used nationwide as a germ-killing ingredient in soaps, deodorants and even toothpaste, but it's being banned in Minnesota.
Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer
PR Newswire - Mon May 19, 1:00PM CDT
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and development (R&D) and technical operations organizations.
Midday Glance: Pharmaceuticals companies
AP - Mon May 19, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Mon May 19, 12:21PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Mon May 19, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Mon May 19, 9:37AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Global Anti-Aging Product Market 2014-2018: Beiersdorf AG, L'Oreal, Phosphagenics, Procter & Gamble & Unilever Group Dominate the Market
M2 - Mon May 19, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76jcqj/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The analysts forecast the Global Anti-aging Product market will grow at a CAGR of 6.7% over the period 2013-2018. One of the main drivers is the rising global aging population. This growth is resulting in an increase in the need for anti-aging and age-defying facial products. Consumers are increasingly using anti-aging products made from natural and organic ingredients. Over the years, consumers have started seeking safe products and are now paying more attention to the ingredients in the anti-aging products, preferring those that do not contain chemicals or ingredients that could cause harmful side effects. Typically, anti-aging skincare and hair care products are made from synthetic ingredients, additives, and fillers. Such products could harm skin and hair, or even weaken and loosen skin when it starts aging. Natural oils such as argan, marula, coconut, and almond are some popular ingredients used in organic products. As organic products have little harmful effects, many large companies are launching natural and organic products to gain more market share. Further, the report states that one of the main challenges hindering market growth is the intensifying competition in the market caused by the entrance of new players and private labels. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. For more information visit http://www.researchandmarkets.com/research/76..._antiaging
1 Biotech Refusing to Stick Its Neck Out
Cory Renauer, The Motley Fool - Motley Fool - Mon May 19, 8:30AM CDT
Pharmacyclics confused the market earlier this month with some shockingly conservative Imbruvica guidance. Sales of the breakthrough leukemia therapy have rocketed upwards since its launch late last year, so the suggestion that it will level off...
Research and Markets: Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bshw3d/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
Research and Markets: Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4qb8z/kappaproct) has announced the addition of the "Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
Emmi Solutions Shares Best Practices and Outcomes at Patient Experience Summit
Marketwire - Mon May 19, 6:30AM CDT
Emmi Solutions, a leader in outcomes-driven patient engagement, will be leading multiple discussions and presenting original research at Cleveland Clinic's "2014 Patient Experience: Empathy + Innovation Summit". The conference brings together patient experience leaders, healthcare CEOs, nursing leaders, policy makers and major stakeholders for presentations, debate and candid discussion of key strategies that drive patient experience and engagement.
Global Abdominal Obesity Clinical Trials Review 2014
M2 - Mon May 19, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qkc4ph/abdominal_obesity) has announced the addition of the "Abdominal Obesity Global Clinical Trials Review, H1, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Abdominal Obesity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Abdominal Obesity. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Genfit SA - Lithera, Inc. - AstraZeneca PLC - Sanofi - Novartis AG - Hanmi Science Co., Ltd. - Parry Nutraceuticals - Kythera Biopharmaceuticals, Inc. - Johnson & Johnson - Queen's University - Massachusetts General Hospital - University of Pittsburgh - Wake Forest University - Baker IDI Heart and Diabetes Institute - Rush University Medical Center - UMC Utrecht Holding BV - Southeast University - Washington University School of Medicine - Maastricht University Medical Center For more information visit http://www.researchandmarkets.com/research/qk...al_obesity
Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rhzq3p/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited. Th1 cells produce large amounts of an inflammatory protein called INF-?, which, in turn, induces the production of the pro-inflammatory cytokine TNF-a in both local and recruited macrophages, as well as in the intestinal epithelial cells Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Remicade (infliximab) 7 Appendix For more information visit http://www.researchandmarkets.com/research/rhzq3p/remicade About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wrdj75/kappaproct) has announced the addition of the "Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. InDeX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of immunological treatments for diseases with a high unmet need. The company is dedicated to developing personalized treatments and diagnostic assays that will allow physicians to predict which patient populations will respond to specific biologics. InDeX developed Kappaproct with the goal of addressing a significant unmet need in severe UC patients, which is the lack of an effective treatment. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Kappaproct including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Kappaproct for the top five countries from 2012 to 2022. - Sales information covered for France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Kappaproct (DIMS 0150) 9 Appendix For more information visit http://www.researchandmarkets.com/research/wrdj75/kappaproct
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
5 Health-Care Stocks With 36 or More Years of Dividend Increases
Sean Williams, The Motley Fool - Motley Fool - Sun May 18, 9:31AM CDT
According to Susanna Kim of ABC News, between 1910 and 2010, dividend yield and dividend growth represented 90% of stockholders' nominal returns . Dividends really are the "X factor" that can alter your retirement and investing strategy, allowing...
This Diversified Health Care Portfolio Could Yield You 4.2% Annually!
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 10:32AM CDT
Just two weeks ago I encouraged health-care sector income investors to take a step back and evaluate the quality of dividends they were receiving. While it's not as if big pharma is twiddling its thumbs while paying out hefty dividends, it's...
Whistleblower Payments Top $300 Million Under False Claims Act in Fiscal Year 2014
PRWeb - 2 hrs 39 mins ago
A review of press releases issued by the Department of Justice since October 1, 2013 conducted by Young Law Group reveals that whistleblowers have been awarded more than $300 million from settlements in qui tam lawsuits in the current fiscal year. The federal government's fiscal year begins on October 1st, leaving more than four months left to add to the impressive amount so far.
Final Glance: Pharmaceuticals companies
AP - Mon May 19, 6:54PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Mon May 19, 6:54PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Minnesota bans anti-bacterial chemical from soaps
By STEVE KARNOWSKI - AP - Mon May 19, 5:22PM CDT
MINNEAPOLIS (AP) — It's widely used nationwide as a germ-killing ingredient in soaps, deodorants and even toothpaste, but it's being banned in Minnesota.
Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer
PR Newswire - Mon May 19, 1:00PM CDT
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and development (R&D) and technical operations organizations.
Midday Glance: Pharmaceuticals companies
AP - Mon May 19, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Mon May 19, 12:21PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Mon May 19, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Mon May 19, 9:37AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Global Anti-Aging Product Market 2014-2018: Beiersdorf AG, L'Oreal, Phosphagenics, Procter & Gamble & Unilever Group Dominate the Market
M2 - Mon May 19, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76jcqj/global_antiaging) has announced the addition of the "Global Anti-Aging Product Market 2014-2018" report to their offering. The analysts forecast the Global Anti-aging Product market will grow at a CAGR of 6.7% over the period 2013-2018. One of the main drivers is the rising global aging population. This growth is resulting in an increase in the need for anti-aging and age-defying facial products. Consumers are increasingly using anti-aging products made from natural and organic ingredients. Over the years, consumers have started seeking safe products and are now paying more attention to the ingredients in the anti-aging products, preferring those that do not contain chemicals or ingredients that could cause harmful side effects. Typically, anti-aging skincare and hair care products are made from synthetic ingredients, additives, and fillers. Such products could harm skin and hair, or even weaken and loosen skin when it starts aging. Natural oils such as argan, marula, coconut, and almond are some popular ingredients used in organic products. As organic products have little harmful effects, many large companies are launching natural and organic products to gain more market share. Further, the report states that one of the main challenges hindering market growth is the intensifying competition in the market caused by the entrance of new players and private labels. Key Vendors - Beiersdorf AG - L'Or?al SA - Phosphagenics Ltd. - Procter & Gamble Co. - Unilever Group Other Prominent Vendors - Allergan Inc. - Amexdrug Corp. - Avon Products Inc. - Chanel SA - Christian Dior SA - Clarins USA Inc. - DS Healthcare Group Inc. - Elizabeth Arden Inc. - Ella Bach? - Est?e Lauder Co. Inc. - Henkel AG & Co KGaA - Jan Marini Skin Research Inc. - Johnson & Johnson Co. - Kao Corp. - NeoStrata Co. - NuSKin Enterprises - Orlane SA - Revlon Inc. - Robanda International Inc. - Shiseido Co. - SkinMedica Inc. - Skinvisible Inc. - Woodridge Labs Inc. For more information visit http://www.researchandmarkets.com/research/76..._antiaging
1 Biotech Refusing to Stick Its Neck Out
Cory Renauer, The Motley Fool - Motley Fool - Mon May 19, 8:30AM CDT
Pharmacyclics confused the market earlier this month with some shockingly conservative Imbruvica guidance. Sales of the breakthrough leukemia therapy have rocketed upwards since its launch late last year, so the suggestion that it will level off...
Research and Markets: Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 7:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bshw3d/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
Research and Markets: Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Mon May 19, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q4qb8z/kappaproct) has announced the addition of the "Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
Emmi Solutions Shares Best Practices and Outcomes at Patient Experience Summit
Marketwire - Mon May 19, 6:30AM CDT
Emmi Solutions, a leader in outcomes-driven patient engagement, will be leading multiple discussions and presenting original research at Cleveland Clinic's "2014 Patient Experience: Empathy + Innovation Summit". The conference brings together patient experience leaders, healthcare CEOs, nursing leaders, policy makers and major stakeholders for presentations, debate and candid discussion of key strategies that drive patient experience and engagement.
Global Abdominal Obesity Clinical Trials Review 2014
M2 - Mon May 19, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qkc4ph/abdominal_obesity) has announced the addition of the "Abdominal Obesity Global Clinical Trials Review, H1, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Abdominal Obesity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Abdominal Obesity. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Genfit SA - Lithera, Inc. - AstraZeneca PLC - Sanofi - Novartis AG - Hanmi Science Co., Ltd. - Parry Nutraceuticals - Kythera Biopharmaceuticals, Inc. - Johnson & Johnson - Queen's University - Massachusetts General Hospital - University of Pittsburgh - Wake Forest University - Baker IDI Heart and Diabetes Institute - Rush University Medical Center - UMC Utrecht Holding BV - Southeast University - Washington University School of Medicine - Maastricht University Medical Center For more information visit http://www.researchandmarkets.com/research/qk...al_obesity
Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rhzq3p/remicade) has announced the addition of the "Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited. Th1 cells produce large amounts of an inflammatory protein called INF-?, which, in turn, induces the production of the pro-inflammatory cytokine TNF-a in both local and recruited macrophages, as well as in the intestinal epithelial cells Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Remicade (infliximab) 7 Appendix For more information visit http://www.researchandmarkets.com/research/rhzq3p/remicade About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Mon May 19, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wrdj75/kappaproct) has announced the addition of the "Kappaproct (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. InDeX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of immunological treatments for diseases with a high unmet need. The company is dedicated to developing personalized treatments and diagnostic assays that will allow physicians to predict which patient populations will respond to specific biologics. InDeX developed Kappaproct with the goal of addressing a significant unmet need in severe UC patients, which is the lack of an effective treatment. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Kappaproct including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Kappaproct for the top five countries from 2012 to 2022. - Sales information covered for France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Kappaproct (DIMS 0150) 9 Appendix For more information visit http://www.researchandmarkets.com/research/wrdj75/kappaproct
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
5 Health-Care Stocks With 36 or More Years of Dividend Increases
Sean Williams, The Motley Fool - Motley Fool - Sun May 18, 9:31AM CDT
According to Susanna Kim of ABC News, between 1910 and 2010, dividend yield and dividend growth represented 90% of stockholders' nominal returns . Dividends really are the "X factor" that can alter your retirement and investing strategy, allowing...
This Diversified Health Care Portfolio Could Yield You 4.2% Annually!
Sean Williams, The Motley Fool - Motley Fool - Sat May 17, 10:32AM CDT
Just two weeks ago I encouraged health-care sector income investors to take a step back and evaluate the quality of dividends they were receiving. While it's not as if big pharma is twiddling its thumbs while paying out hefty dividends, it's...
